BioSpace News Archive

Eli Lilly and Company will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021.

Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced the Company will present at the H.C. Wainwright Virtual BioConnect Conference taking place January 11-14, 2021.

After launching a “serosurvey” to track undetected cases of COVID-19 in the US, the National Institutes of Health (NIH) published a paper in Nature Communications on its serology study for development of an ELISA that detects SARS-CoV-2 antibodies with 99-100% specificity.

Minnesota dentists are offering free dental care for children in need on February 5 and 6, 2021.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 91,800 shares of its common stock to two new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan (the “Indu

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11 th at 12:40 p.m. PST / 3:40 p.m. EST . Charles M. Baum , M.D., Ph.D., Mirati’s President and Chief Executive Officer will present at the con

ViewRay, Inc., maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, announced that it has commenced an underwritten public offering of shares of its common stock.

Universal Health Services, Inc. (NYSE: UHS) announced today that Steve Filton , Executive Vice President and Chief Financial Officer will present at the 39 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA , on Monday, January 11, 2021 at 10:50 a.m. (Eastern Time) . A live audio webcast of the presentatio

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 23,350 shares of common stock and 5,675 restricted stock units (“RSUs”) to be distributed among three new

AdaptHealth Corp. announced that it has commenced an underwritten public offering of 7,000,000 shares of its Class A Common Stock, and certain selling stockholders intend to offer and sell an additional 1,000,000 shares of the Company’s Class A Common Stock, subject to market and other conditions.